
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 24, 2011

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California
(State or Other Jurisdiction
of Incorporation)

001-14758
(Commission File Number)

33-0476164
(I.R.S. Employer
Identification No.)

1300 Kellogg Drive, Suite D, Anaheim, California
(Address of Principal Executive Offices)

92807
(Zip Code)

Registrant's telephone number, including area code: (714) 786-4200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On February 24, 2011, Questcor Pharmaceuticals, Inc. (the "Company") announced via a press release that it will be making presentations to certain members of the investment community and, in connection therewith, will provide an updated presentation including certain additional and revised information about the Company. A copy of the Company's press release is attached hereto as Exhibit 99.1. The presentation to be provided to the investment community will be made available on the Company's website at www.Questcor.com as soon thereafter as practicable. The presentation is furnished under this Item 7.01 pursuant to Regulation FD and is included as Exhibit 99.2 to this Current Report on Form 8-K.

The Company will host a live webcast covering the presentations to be held on March 1, 2011 at 9:00 a.m., E.T., March 2, 2011 at 11:30 a.m., E.T., and March 7, 2011 at 4:00 p.m., E.T. To access the live webcast of a particular presentation, please go to the Company's website at www.Questcor.com at the aforementioned time. An archived webcast of each of the listed presentations will also be available at www.Questcor.com.

In accordance with General Instruction B.2. of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Questcor Pharmaceuticals, Inc. press release dated February 24, 2011.
99.2	Questcor Pharmaceuticals, Inc. March 2011 Investor Presentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 28, 2011

QUESTCOR PHARMACEUTICALS, INC.

By: _____ /s/ MICHAEL H. MULROY
Michael H. Mulroy, Senior Vice
President, Chief Financial Officer and
General Counsel

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Questcor Pharmaceuticals, Inc. press release dated February 24, 2011.
99.2	Questcor Pharmaceuticals, Inc. March 2011 Investor Presentation.

Questcor Pharmaceuticals to Present at Upcoming Investor Conferences

ANAHEIM, Calif., Feb. 24, 2011 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that executive management will present at the following investor conferences during the first week of March 2011:

- The Citi Global Healthcare Conference in New York City. Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, March 1, 2011 at 9:00 a.m. ET.
- The RBC Capital Markets Healthcare Conference in New York City. Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Wednesday, March 2, 2011 at 11:30 a.m. ET.
- The Cowen and Company Healthcare Conference in Boston. David Young, Pharm.D., Ph.D., Chief Scientific Officer, is scheduled to present an overview of the Company on Monday, March 7, 2011 at 4:00 p.m. ET.

To listen to the audio web cast of a presentation during or after the event, please visit: www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age. Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.





NASDAQ **QCOR**

March 2011

 **QUESTCOR®**

Safe Harbor Statement

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “believe,” “could,” “estimates,” “expects,” “growth,” “may,” “plans,” “potential,” “should,” “substantial” or “will” or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following: Our reliance on Acthar for substantially all of our net sales and profits; The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions; The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products; Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar; Research and development risks, including risks associated with Questcor’s preliminary work in the area of nephrotic syndrome and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results; Regulatory changes or other policy actions by governmental authorities and other third parties as recently adopted U.S. healthcare reform legislation is implemented; Our ability to receive high reimbursement levels from third party payers; An increase in the proportion of our Acthar sales comprised of Medicaid-eligible patients and government entities; Our ability to estimate reserves required for Acthar due by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid sales may have upon our results; Our ability to operate within an industry that is highly regulated at both the Federal and state level; Our ability to effectively manage our growth and our reliance on key personnel; The impact to our business caused by economic conditions; Our ability to protect our proprietary rights; Our ability to maintain effective controls over financial reporting; The risk of product liability lawsuits; Unforeseen business interruptions; Volatility in Questcor’s monthly and quarterly Acthar shipments and end-user demand, as well as volatility in our stock price; and Other risks discussed in Questcor’s annual report on Form 10-K for the year ended December 31, 2010 and other documents filed with the Securities and Exchange Commission.

The risk factors and other information contained in these documents should be considered in evaluating Questcor’s prospects and future financial performance.

Questco Overview

**A biopharmaceutical company
whose product helps patients with serious,
difficult-to-treat medical conditions**



Questco Overview

Flagship Product: H.P. **Acthar**[®] GEL
(repository corticotropin injection) 80 U/mL

- 19 approved indications

Key Markets:

- Multiple Sclerosis, Infantile Spasms, Nephrotic Syndrome
- Combined markets opportunity exceeds \$1.5 billion

Strategy:


- Grow Acthar sales in each key market

Financials:


- Profitable, cash flow positive, \$127M in cash, debt-free



History of Acthar



Significant Barriers to Entry




QuestcoGrowth Engine

Multiple Sclerosis (MS)

Infantile Spasms (IS)

Nephrotic Syndrome (NS)

Large Market Opportunity




*Represents estimated net sales market opportunity based on internal company estimates

** Represents approximate current net sales annualized run rate based on internal company estimates

Actharand MS


- Neurodegenerative disorder
- Acute treatment for relapses
- Dosing period is 1-2 weeks*
- \$40K-\$50K/Rx



 QUESTCOR®

*Based on prescription data

MS Sales Record of Consistent Growth



Numbers in the bars show the number of sales people making calls at the end of the quarter.

New Paid Rx's



Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" uses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the table.

Multiple Sclerosis

400,000
US Prevalence

200,000 – 250,000
Relapses Annually for
MS Patients

10,000 – 70,000
Relapses Annually:
Estimated
Market for Acthar

1,400
Relapses Annually:
Currently Treated
with Acthar

\$500M to \$2B+
Potential Market



*Data on this slide is based on US only. Based on internal company estimates.

MS Trends

- Q4-2010 results
 - Q4-10 new paid Rx's up 66% vs. Q409
 - MS sales over 50% of QCOR sales
 - Over \$65M annualized run rate
 - Approximately one in six Rx's a repeat patient
- Growing number of Acthara prescribers
 - But only ~400 out of 8,000 neurologists
- Speakers bureau growing

MS Sales Calls vs. Paid New Rx's



*MS call data approximate

Sales Force Expansion

- Doubled sales force: hiring/training Aug-Oct 2010 (38 to 77 sales reps)
- Newly expanded sales force began call activity Nov 1
 - Significant increase in MS-treating neurologists targeted for sales calls
 - Now also targeting child neurologists for IS sales calls
- MS paid Rx's increasing since November 1
 - **November matched previous monthly record**
 - **December set new record**
 - **January near previous record level**
 - **February set new record**

Infantile Spasms

- Devastating, refractory form of childhood epilepsy
 - Very poor developmental outcome if inadequately treated
- Not responsive to standard anti-epileptic drugs
- Ultra-rare orphan disorder
 - 1,500 to 2,000 patients annually
- Typically occurs in children less than 2 years old
- Characterized by
 - “spasms”-- a specific type of seizure
 - “hypsarrhythmia”-- abnormal EEG pattern

Actharand IS

- Used by over half of child neurologists
- FDA approval 10/15/10
 - 7 year orphan exclusivity for IS indication
- Crisis therapy
- Treatment for 2-4 weeks*
- In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone
- \$100K-\$125K/Rx
 - About half of patients receive drug for free



*Based on prescription data

IS Sales Plan

- Significant variability in quarterly prescriptions
- Q4-2010 sales within historic range
- Promotion effort began 11/1/10
- Potential to increase IS revenue
 - Acthar currently used to treat 30-50% of IS patients



Nephrotic Syndrome

- Characterized by excessive spilling of protein from the kidney into the urine (proteinuria)
- Can result in end-stage renal disease (ESRD), dialysis, transplant
- Significant unmet need
 - Few treatment options

Actharand NS

- FDA-approved on label indication for reduction of proteinuria in:
 - Idiopathic types of nephrotic syndrome
 - Idiopathic membranous nephropathy
 - Focal segmental glomerular sclerosis (FSGS)
 - IgA nephropathy
 - Lupus nephritis
- Treatment for 4-6 months*
- \$150K-250K/Rx

Proof of Concept Data

- Available November 2010
- Case series showed response from Actharrefractory idiopathic membranous nephropathy (on-label)
 - 9 of 11 patients met response criteria
- Positive signal received in diabetic nephropathy investigator initiated trial (not on-label)
 - 9 of 15 patients on Acthamet response criteria and none have required dialysis

R&D Effort in NS

- Dose response trial for idiopathic membranous nephropathy (on-label)
 - \$5-7M multi-center trial, n~100
 - Reduction of proteinuria as endpoint
- Presently designing a well controlled study in collaboration with FDA for diabetic nephropathy (off-label)
 - Proof-of-concept study with different dosing regimens and a placebo
 - Objectives will be to determine if Acthar is efficacious and safe in a placebo controlled study
 - If successful, next step will be a larger Phase II trial

NS Business Plan

- Nov 2010 ASN meeting
 - First meeting with commercial team presence
 - Data presented via podium/posters
 - 30+ doctor advisory board meeting
- Hired 5 reps to sell Acthar to nephrologists
 - Develop selling process and generate sales
 - Initiate sales efforts in early March 2011
 - Expand sales force if sales increase
- Peer review publication of case series in March 2011

Immediate Acthar® Growth Opportunities

- MS - Build on sales momentum, lots of market headroom
- IS - Incremental market share growth
- NS - Establish Acthar as a therapeutic alternative in this sizeable market



*Represents estimated net sales market opportunity based on internal company estimates

** Represents approximate current net sales annualized run rate based on internal company estimates

Financials

Profitable

Debt Free

Cash Flow Positive

2010 Financial Results

Record Sales (up 30%) and Solid Earnings (EPS up 35%)

	2010	2009
Net Sales (\$M)	\$115.1	\$88.3
Gross Margin	93%	92%
Operating Inc (\$M)	\$53.8	\$41.2
EPS	\$0.54	\$0.40

Questcor is Cash Flow Positive

	2/18/11
Cash / ST Investment	\$127M*
Accounts Receivable	\$17M

*After return of \$67 million of cash to shareholders through share repurchases.

Debt-free balance sheet


Go Forward Plan Sell More Acthar

- Expanded sales force to pursue MS/IS
- Dedicated pilot NS sales team starting March 2011
- Develop other markets for Acthar
 - Acthar is its own pipeline with 15 other on-label and many possible other therapeutic uses
 - Further defining and developing the unique characteristics of Acthar
- No business development efforts planned



Investment Highlights

- Questcoris streamlined, focused & profitable
- Actharhas sustainable competitive advantages
- Focus on substantial growth in MS sales
- Recent IS approval/label modernization
- Possible upside with NS
- Market sizes have good growth potential
- Cash flow positive/no debt





NASDAQ **QCOR**

March 2011

 **QUESTCOR®**



QUESTCOR®